Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

by Timothy McQuiston, Vermont Business Magazine The Vermont Department of Health reported last week that the number of COVID-19 hospitalizations remains low, at under 5 after a spike in January.

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Laboratory-confirmed and diagnosed COVID-19 cases and COVID-19 outbreaks must still be reported to the Vermont Department of ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...